Key facts
- Nuvaira’s last known valuation is $139.3M (Nov 2023).
- It has raised $244.0M across 6 recorded rounds; the latest was Early Stage VC ($35.8M) in Feb 2026.
- Notable investors include Qiming Venture Partners USA, Vertex Growth, Lightstone Ventures, Versant Ventures, Richard King Mellon Foundation — 14 tracked in total.
- Nuvaira has filed 8 Form Ds with the SEC since 2018, most recently Aug 2025 ($979K sold to 8 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 6 rounds
- ·The complete investor list — 14 names
- ·Watchlist + deal alerts for Nuvaira
Funding rounds
6 roundsAbout Nuvaira
Developer of a medical device designed to improve outcomes for patients suffering from obstructive lung diseases. The company's device is a novel, catheter-based system to treat overactive airway nerves, a common disease feature of both COPD and asthma, enabling physicians to reduce the clinical consequences of neural hyperactivity.
- Sector
- Healthcare
- HQ
- Maple Grove, MN, United States
- Founded
- 2008
- Employees
- 35
- Website
- nuvaira.com/
- Ownership
- Privately Held (backing)
Nuvaira doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Nuvaira shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Nuvaira in its N-PORT filings yet. We sweep new filings monthly.